Return to homepagePandemic Pact

Antiviral compounds against CoV-2 helicase (Antiviralt läkemedel mot CoV-2 helicase)

Grant number: 2020-05836

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020

  • Known Financial Commitments (USD)

    $69,187.74

  • Funder

    Swedish Research Council

  • Principal Investigator

    Anders Sönnerborg

  • Research Location

    Sweden

  • Lead Research Institution

    Karolinska Institutet

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

We have discovered a compound that inhibits nsp13 of SARS-CoV nsp13, MERS-CoV and mouse hepatitis coronavirus. We hypothesize that the compound and its derivates inhibit CoV-2 helicase, with the same mechanism of action. Thereby broad-spectrum coronavirus inhibitors can be identified. Hence, in the project we will determine the inhibition mechanism of the lead compound on SARS-CoV-2 and identify broad-spectrum related compounds which will be evaluated in vitro assays for cytotoxicity and antiviral efficacy. Also any drug resistance pattern will be determined. Mikrobiologi inom det medicinska området

2 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

Cell-type-resolved quantitative proteomics map of interferon response against SARS-CoV-2.

Infectivity of SARS-CoV-2: there Is Something More than D614G?